Rain Therapeutics Inc. Profile Avatar - Palmy Investing

Rain Therapeutics Inc.

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, …

Biotechnology
US, Newark [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Rain Therapeutics Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Rain Therapeutics Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Rain Therapeutics Inc..

End of RAIN's Analysis
CIK: 1724979 CUSIP: 75082Q105 ISIN: US75082Q1058 LEI: - UEI: -
Secondary Listings
RAIN has no secondary listings inside our databases.